期刊文献+

慢性肾功能不全通过下调ABCA1表达影响巨噬细胞内胆固醇含量 被引量:2

Chronic renal failure influences macrophages' cholesterol content by down-regulating ABCA1
下载PDF
导出
摘要 目的探讨慢性肾功能不全患者巨噬细胞内胆固醇含量的变化及ATP结合盒受体A1(ATP binding cassettetransporter-A1,ABCA1)的表达情况。方法选取2010年8月至2012年3月重庆医科大学第一附属医院住院的慢性肾功能不全(chronic renal failure,CRF)患者30例和健康对照组20例。分离外周血单核细胞诱导贴壁巨噬化,油红O染色鉴定,应用酶法测定巨噬细胞内胆固醇含量,应用real-time PCR与Western blot方法测定细胞ABCA1的mRNA及蛋白表达。结果慢性肾功能不全患者巨噬细胞内胆固醇含量明显高于健康对照组(P<0.01),ABCA1在慢性肾功能不全患者巨噬细胞中的mRNA与蛋白表达显著低于健康对照组(P<0.01)。结论慢性肾功能不全患者巨噬细胞的胆固醇含量明显增加,胆固醇含量增加与慢性肾功能不全患者ABCA1的表达下调有关。 Objective To explore the changes of cholesterol content and the expression of ABCA1 in peripheral macrophages from chronic renal failure (CRF) patients. Methods A total of 30 CRF patients hospitalized in our department from August 2010 to March 2012 and 20 sex- and age-matched healthy volunteers were enrolled in this study. Peripheral blood mononuclear cells (PBMCs) were isolated and stimulated to make them transfer to macrophages. Maerophages were identified by oil red O staining. The cellular cholesterol content was measured by enzymatic colorimetry. Macrophages were collected to detect the expression of ABCA1 by real-time PCR and Western blotting. Results The content of intracellular cholesterol in the peripheral macrophages from CRF patients was significantly higher than that from healthy patients (P 〈 0. 01 ), while, the expression of ABCA1 was significantly decreased (P 〈 0.01 ). Conclusion CRF increases cholesterol content in peripheral macrophage, which might be associated with the decreased expression of ABCA1.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2013年第6期543-546,共4页 Journal of Third Military Medical University
基金 重庆市卫生局重点项目(2010-1-16)~~
关键词 ABCA1 胆固醇含量 慢性肾功能不全 ABCA1 cholesterol content chronic renal failure
  • 相关文献

参考文献14

  • 1Weiner D E, Tahatahai S, Tighiouiirt H, et al. Canliovasculai- (Hitcomesanti all-cause nKirlalily: exploring the inleraction(:K1) and canlio-vascular disease[J]. Am J Kidney Dis, 2006, 48(3) : 392 -401.
  • 2Vaziri N D, Navab M, Fogelnian A M. HDl. mHal>oli.sm and activity inchnmic kidney disease[j]. Nat Rev \eplm>l, 2010, 6(5) : 287 - 296.
  • 3Go A S, Chertow G M, Fan D, el al. Ommic kidney disease and tht*risks of death, cardiovascular events, and hospitalization[ J]. N Kngl JMed, 2004, 351(13): 1296 -1305.
  • 4Vaziri N D, Norris K. Lipid disorders and their relevance lo ouU-onics inchmnic kidney disease]; J]. B1(hkI Purif , 2011, 31( 1/3): 189 - 196.
  • 5Uu X,Xiong S L, Yi G II. AHCAl , ABCG1,and SR-UI: Transit ofH 1)1,associated sphingosine-I -phosphate[ J ]. Clin Chim Acta, 2()12,413(3/4) : 384-390.
  • 6Zuo Y,Yancey P, Castro 1, et al. Renal dysfunction potentiates foamcell fonnation l)y repressing ABCA1 [ J]. Ailerioscler Thromb Vase Bi-ol, 2009, 29(9) : 1277 -1282.
  • 7Tsimiluxlinios V,Dounousi K, Siamopoulos K C. Dyslipidemia in chro-nic kidney disease : an approach to pathogenesis and treatment [ J ]. AmJ Nephrol, 2008, 28(6) : 958 -973.
  • 8Gian D T, lrisli A B, Dogra G K, etal. Dyslipidaemia and cardiorenaldisease : mechanisms, thera|)eutic opportunities and clinical trials[ J ].Atlierosclemsis, 2008, 196( 2) : 823 -834.
  • 9Vaziri N 0. Dyslipidemia of chronic renal failure: the nature, mecha-nisms, and potrntial consequences [ J ] . Am J Physiol Renal Physiol,2006,290(2) : F262 -F272.
  • 10Vaziri N D, Yuan J,Ni Z, et al. Lipoprotein lipase deficiency in chronickidnev disease is accompanist! by down-regulation of endothelial GPIH-BP1 exprt'ssionf J]. Clin K\}> Nrplm*!, 2012,16(2) : 238 - 243.

同被引文献20

  • 1杨小兵,侯凡凡,武强,周华,刘郑荣,杨燕,张训.慢性肾脏病患者晚期氧化蛋白产物血症及其与动脉粥样硬化的关系[J].中华内科杂志,2005,44(5):342-346. 被引量:41
  • 2Jiang Z,Zhou R, Xu C,et al. Genetic valiation of the ATP- binding cassette transporter A1 and susceptibility to coronary heart disease [J]. Mol Genet Metab, 2011,103(1 ) : 81-88.
  • 3Pelham CJ,Keen HL,Lentz SR,et al. Dominant negative PPARv promotes atheroselerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle [J]. Am J Physiol Regul Integr Comp Phys- iol, 2013,304: R690-R701.
  • 4Wang N, Yin R, Liu Y, et al. Role of peroxisome prolifera- toractivated receptor-gamma in atherosclerosis:an update [J]. Cire J, 2011,75 (2) : 528-535.
  • 5Lim S, Despres JP,Koh KK. Prevention of atheroselerosis in overweight/obese patients in need of novel multi-tar- geted approaches [J]. Circ J, 2011,75 (5) : 1019-1027.
  • 6Toyama K,Nakamura T,Kataoka K,et al. Telmisartan pro- tects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes,partially through peroxisome proliferator activated receptor-gamma-depen- dent activity [J]. Bioehem Biophys Res Commun,2011,410 (10) :508-513.
  • 7Hu Q,Zhang XJ,Liu CX,et al. Ppargammal-induced cave- olin-1 enhances cholesterol efflux and attenuates atherosele- rosis in apolipoprotein E--deficient mice [J]. J Vase Res,2010, 47: 69-79.
  • 8Ozasa H, Ayaori M, Iizuka M, et al. Pioglitazone enhances cholesterol efflux from macrophagesby increasing ABCA1/ ABCG1 expressions via PPAR gamma/LX Ralpha path- way:findings from in vitro and ex vivo studies [J]. Atheroscle- rosis, 2011,219:141-150.
  • 9Hamblin M, Chang L, Zhang H, et al. Vascular smooth mus- cle cell peroxisome proliferator-activated receptor-gam- ma mediates pioglitazone-reduced vascular lesion forma- tion [J]. Arterioscler Thromb Vasc Biol,2011,31:352-359.
  • 10Jing Wu, Yahua Zhang, Nanping Wang, et al. Liver X re- ceptor-alpha mediates cholesterol etilux in glomerular mesangial cells [J]. Am J Physiol Renal Physiol,2004,287 (5) :F886-F895.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部